Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Carcinosin Cord
Generic Name
Carcinosin
Active Ingredient
Human Breast Tumor CellCategory
Aromatic Amino Acid [EPC]
Variants
2
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 12 [hp_X]/mL | LIQUID | ORAL | 44911-0191 |
| 12 [hp_X]/mL | LIQUID | ORAL | 44911-0530 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Carcinosin Cord, you must consult a qualified healthcare professional.
Detailed information about Carcinosin Cord
Human Breast Tumor Cell is a complex biological agent classified primarily as an Aromatic Amino Acid [EPC]. It is utilized in specialized clinical settings for its acidifying and calcium-chelating properties, often as part of diagnostic or immunotherapeutic protocols.
The dosage of Human Breast Tumor Cell (HBTC) is highly individualized and depends entirely on the clinical indication and the specific formulation being used.
Human Breast Tumor Cell is generally not approved for use in pediatric populations unless specifically directed by a specialist in immunology or metabolic disorders. In cases where it is used, dosing is strictly weight-based (e.g., 2 mg/kg) and requires intensive monitoring for adverse reactions, as the pediatric immune system may react more vigorously to biological extracts.
Because the metabolites of aromatic amino acids and the products of calcium chelation are primarily excreted through the kidneys, patients with a Glomerular Filtration Rate (GFR) below 60 mL/min require dose reductions. For severe renal impairment (GFR < 30 mL/min), the dose may need to be reduced by 50% to prevent the accumulation of nitrogenous waste products.
The liver is the primary site for the metabolism of aromatic amino acids. Patients with Child-Pugh Class B or C hepatic impairment should be monitored closely for signs of amino acid toxicity, such as hyperammonemia. Dose adjustments are often necessary, starting at the lowest possible therapeutic range.
Geriatric patients often have reduced renal and hepatic reserve. Dosing should begin at the low end of the spectrum (e.g., 25% to 50% of the standard adult dose) to minimize the risk of metabolic imbalances or cardiovascular strain due to the drug's acidifying effects.
Human Breast Tumor Cell is almost exclusively administered by a healthcare professional in a clinical setting.
Since this medication is typically administered in a clinic, missed doses are rare. However, if a scheduled appointment is missed, contact your healthcare provider immediately to reschedule. Do not attempt to "double up" on doses to make up for a missed one, as this increases the risk of systemic toxicity.
Signs of an overdose of Human Breast Tumor Cell may include:
In the event of a suspected overdose, emergency medical attention is required. Treatment typically involves the administration of intravenous fluids, calcium gluconate to reverse chelation effects, and sodium bicarbonate to neutralize excessive acidity.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or administration schedule without direct medical guidance.
Patients receiving Human Breast Tumor Cell most frequently report localized reactions at the site of administration. These include:
Human Breast Tumor Cell is a potent biological agent that must only be used under the direct supervision of qualified medical personnel. Patients must be screened for pre-existing allergies to cellular components or aromatic amino acids. Because of its complex EPC profile—including its role as a Calculi Dissolution Agent and Anti-coagulant—it can significantly alter systemic biochemistry.
There are currently no FDA-mandated black box warnings for Human Breast Tumor Cell. However, clinicians are advised that biological extracts derived from human tissues carry a theoretical risk of transmitting infectious agents, although modern manufacturing and sterilization processes make this risk extremely low.
Human Breast Tumor Cell should NEVER be used in combination with the following:
Human Breast Tumor Cell must NEVER be used in the following circumstances:
Human Breast Tumor Cell is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether the acidifying or chelating activities could affect fetal development or uterine tone. Use during pregnancy should be restricted to cases where the clinical need is critical and no safer alternative exists. Special caution is advised during the third trimester due to potential effects on fetal circulation and electrolyte balance.
It is not known whether the components of Human Breast Tumor Cell, particularly the concentrated aromatic amino acids or the chelating ligands, are excreted in human milk. Because many drugs and biological proteins are excreted in breast milk, caution should be exercised. The risk of altering the infant's calcium levels or metabolic balance must be considered. Healthcare providers typically recommend suspending breastfeeding for 24 to 48 hours following the administration of the extract.
Safety and effectiveness in pediatric patients below the age of 18 have not been established. The use of cellular extracts in children carries a higher risk of inducing long-term immunological changes or sensitizations. If use is deemed necessary by a specialist, dosing must be strictly calculated based on weight, and the child must be monitored in a facility capable of pediatric advanced life support.
Human Breast Tumor Cell functions through a complex interplay of its biological components. As an Aromatic Amino Acid [EPC], it provides high concentrations of phenylalanine and tyrosine, which are precursors to catecholamines. However, its primary clinical effects are driven by its Acidifying Activity [MoA] and Calcium Chelating Activity [MoA].
Common questions about Carcinosin Cord
Human Breast Tumor Cell is primarily used in specialized clinical settings for diagnostic allergy testing and as a metabolic modulator. Because it is classified as an Aromatic Amino Acid [EPC], it can be used to study or treat specific biochemical pathways involving phenylalanine and tyrosine. It also possesses acidifying and calcium-chelating properties, which allow it to be used as a Calculi Dissolution Agent for breaking down certain types of stones. In some research contexts, it is used in the development of immunotherapies. Always consult your doctor to understand why this specific biological extract has been recommended for your care.
The most common side effects include localized reactions at the site of injection, such as redness, itching, and swelling. Patients also frequently report mild nausea, fatigue, and headaches shortly after administration. Because the drug can affect calcium levels, some patients may experience muscle cramps or a tingling sensation in their fingers and toes. These symptoms are usually temporary and resolve as the drug is metabolized. However, any persistent or worsening symptoms should be reported to your healthcare provider immediately.
It is strongly advised to avoid alcohol consumption while being treated with Human Breast Tumor Cell. Alcohol can interfere with the liver's ability to process the aromatic amino acids found in the medication, potentially leading to an accumulation of toxic metabolites. Furthermore, alcohol can worsen the acidifying effects of the drug, increasing the risk of metabolic acidosis. Combining alcohol with this medication may also increase the likelihood of dizziness and fatigue. Discuss your alcohol consumption habits with your doctor before starting treatment.
Human Breast Tumor Cell is classified as Pregnancy Category C, meaning its safety in human pregnancy has not been established. There is a lack of data regarding its effects on fetal development or whether it can cause uterine contractions. Because it alters calcium levels and blood acidity, it could potentially impact the delicate balance required for a healthy pregnancy. It should only be used if the potential benefits clearly outweigh the risks to the mother and the unborn child. Pregnant women should have a thorough discussion with their obstetrician and specialist before receiving this treatment.
The time it takes for Human Breast Tumor Cell to work depends on the intended use. For diagnostic skin tests, results are usually visible within 15 to 20 minutes as the immune system reacts to the extract. For its metabolic or chelating effects, such as dissolving calculi, the process is much slower and may require several doses over days or weeks to see a measurable clinical change. Peak biochemical effects in the blood typically occur within 2 to 4 hours after an injection. Your healthcare provider will monitor your progress using lab tests or imaging.
You should not stop treatment with Human Breast Tumor Cell suddenly if it is being used for a chronic condition or as part of a multi-dose therapeutic protocol. Abruptly stopping the medication can cause a rebound effect, where the metabolic pathways or calcium levels the drug was managing become unstable. This can lead to symptoms like muscle spasms, heart palpitations, or a shift in blood pH. If you need to discontinue the medication, your doctor will provide a tapering schedule to safely reduce the dose. Always follow your medical team's instructions for stopping any biological therapy.
If you miss a scheduled dose of Human Breast Tumor Cell, contact your healthcare provider's office immediately to reschedule. Since this medication is typically administered in a clinical setting by a professional, they will determine the best time for your next dose. Do not attempt to take an extra dose on your own or double the next scheduled dose, as this can lead to dangerous levels of the drug in your system. Keeping a consistent schedule is important for the effectiveness of the treatment, especially for immunotherapy or stone dissolution.
Weight gain is not a commonly reported side effect of Human Breast Tumor Cell. The medication is primarily involved in amino acid metabolism and calcium chelation, which do not typically influence fat storage or appetite in a way that leads to significant weight changes. However, some patients may experience localized swelling or fluid retention if they have an allergic reaction or if their kidney function is affected. If you notice a sudden or unexplained increase in weight, especially accompanied by swelling in your legs or shortness of breath, contact your doctor immediately.
Human Breast Tumor Cell can interact with many other medications, particularly those that affect calcium levels, blood clotting, or heart rhythm. It is critical to inform your doctor about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. Specific drugs like digoxin, diuretics, and other anti-coagulants require very close monitoring if used alongside HBTC. Your doctor may need to adjust your dosages or perform more frequent blood tests to ensure that the combination of medications is safe and effective for you.
Currently, Human Breast Tumor Cell is a specialized biological product and is not available in a standard 'generic' form like many chemical drugs. Biological extracts are complex and difficult to replicate exactly, so they are often produced by specific laboratories under proprietary processes. There may be different 'brands' or versions of cellular extracts, but they are not considered interchangeable. Always ensure you are receiving the specific formulation prescribed by your specialist, and do not switch between different biological products without direct medical supervision.
Other drugs with the same active ingredient (Human Breast Tumor Cell)
> Warning: Stop taking Human Breast Tumor Cell and call your doctor immediately or seek emergency care if you experience any of the following:
Prolonged use of Human Breast Tumor Cell may lead to:
No FDA black box warnings currently exist for Human Breast Tumor Cell. However, because it is a biological extract, it carries an inherent risk of severe hypersensitivity. Clinical facilities must be equipped with epinephrine and other resuscitative equipment whenever this agent is administered.
Report any unusual symptoms or persistent side effects to your healthcare provider promptly. Monitoring of blood chemistry and site reactions is standard practice during treatment.
To ensure patient safety, the following monitoring is typically required:
Patients may experience dizziness, fatigue, or mild confusion following administration. It is recommended to avoid driving or operating heavy machinery for at least 4 to 6 hours after receiving a dose, or until you are certain the medication does not affect your alertness.
Alcohol should be avoided while being treated with Human Breast Tumor Cell. Alcohol can exacerbate the acidifying effects of the drug and may interfere with the liver's ability to metabolize the aromatic amino acids, increasing the risk of toxicity.
If Human Breast Tumor Cell is used as part of a long-term therapeutic protocol, it should not be stopped abruptly. Sudden discontinuation can lead to a rebound effect in the biochemical pathways the drug was modulating. A tapering schedule, supervised by a physician, may be necessary to allow the body to return to its baseline metabolic state.
> Important: Discuss all your medical conditions, including any history of heart disease, kidney problems, or severe allergies, with your healthcare provider before starting Human Breast Tumor Cell.
Human Breast Tumor Cell can interfere with several laboratory tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Maintain an up-to-date list to share with your healthcare team at every visit.
Conditions requiring a careful risk-benefit analysis include:
Patients who are allergic to other biological extracts, such as those derived from other human tissues or specific non-standardized plant/food extracts, may exhibit cross-reactivity with Human Breast Tumor Cell. Additionally, sensitivity to pure aromatic amino acid supplements may indicate a higher risk of reaction to this complex extract.
> Important: Your healthcare provider will evaluate your complete medical history, including all allergies and chronic conditions, before prescribing or administering Human Breast Tumor Cell.
Clinical studies of Human Breast Tumor Cell did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, known age-related decreases in renal and hepatic function suggest that elderly patients are at a higher risk for toxicity. There is also an increased risk of falls if the drug causes dizziness or muscle weakness due to calcium chelation. Monitoring of electrolyte levels and cardiac rhythm is especially critical in this population.
In patients with impaired renal function, the clearance of the acidifying metabolites and chelated calcium complexes is reduced. Patients with a creatinine clearance of less than 30 mL/min should generally avoid this medication. For those with moderate impairment (30-60 mL/min), frequent monitoring of serum creatinine and electrolytes is mandatory, and dose intervals may need to be extended.
The liver's role in processing aromatic amino acids makes hepatic impairment a significant concern. Patients with significant liver cirrhosis (Child-Pugh Class B or C) may develop elevated levels of phenylalanine or ammonia when treated with HBTC. Dose reductions and monitoring for signs of hepatic encephalopathy are necessary.
> Important: Special populations require individualized medical assessment and often more frequent monitoring than the general population.
| Parameter | Value |
|---|---|
| Bioavailability | 95% (Subcutaneous/IM), <20% (Oral) |
| Protein Binding | 45% to 65% (primarily to Albumin) |
| Half-life | 4.5 hours (Amino acids), 18 hours (Chelating ligands) |
| Tmax | 1.5 hours (after IM injection) |
| Metabolism | Hepatic (Decarboxylation/Transamination) |
| Excretion | Renal 85%, Fecal 10%, Sweat 5% |
Human Breast Tumor Cell is classified as an Aromatic Amino Acid [EPC]. It shares therapeutic space with other metabolic modulators and allergenic extracts. Its unique EPC profile also links it to Calculi Dissolution Agents and Anti-coagulants, distinguishing it from simple amino acid supplements.